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Objective: Ghrelin, a novel growth hormone–releasing peptide, is implicated to play a protective role in cardiovascular tissues.
However, it is not clear whether ghrelin protects vascular tissues from injury secondary to risk factors such as homocysteine
(Hcy). This study investigated the effect and potential mechanisms of ghrelin on Hcy-induced endothelial dysfunction.
Methods: Porcine coronary artery rings were incubated for 24 hours with ghrelin (100 ng/mL), Hcy (50 M), or ghrelin
plus Hcy. Endothelial vasomotor function was evaluated using the myograph tension model. The response to the
thromboxane A2analog U46619, bradykinin, and sodium nitroprusside was analyzed. Endothelial nitric oxide synthase
(eNOS) expression was determined using real-time polymerase chain reaction and immunohistochemistry staining, and
superoxide anion production was documented lucigenin-enhanced chemiluminescence analysis. Human coronary artery
endothelial cells (HCAECs) were treated with different concentrations of Hcy, ghrelin, or antighrelin receptor antibody
for 24 hours, and eNOS protein levels were determined by Western blot analysis.
Results: Maximal contraction with U46619 and endothelium-independent vasorelaxation with sodium nitroprusside
were not different among the four groups. However, endothelium-dependent vasorelaxation with bradykinin (106 M)
was significantly reduced by 34% with Hcy compared with controls (P < .05). The addition of ghrelin to Hcy had a
protective effect, with 61.6% relaxation, which was similar to controls (64.7%). Homocysteine significantly reduced eNOS
expression, whereas ghrelin cotreatment effectively restored eNOS expression to the control levels. Superoxide anion
levels, which were increased by 100% with Hcy, returned to control levels with ghrelin cotreatment. Ghrelin also
effectively blocked the Hcy-induced decrease of eNOS protein levels in HCAECs in a concentration-dependent manner.
Antighrelin receptor antibody effectively inhibited the effect of ghrelin.
Conclusion: Ghrelin has a protective effect in the porcine coronary artery by blocking Hcy-induced endothelial dysfunction,
improving eNOS expression, and reducing oxidative stress. Ghrelin also shows a protective effect on HCACEs from the
Hcy-induced decrease in eNOS protein levels. The effect of ghrelin is receptor-dependent. Thus, ghrelin administration may
have beneficial effects in the treatment of vascular disease in patients with hyperhomocysteinemia. (J Vasc Surg 2009;49:199-207.)
Clinical Relevance: Homocysteine is an independent risk factor for atherosclerosis and other vascular lesions. It causes
endothelial dysfunction and oxidative stress. Ghrelin, a novel growth hormone–releasing peptide, is implicated to play a
protective role in cardiovascular tissues. This study investigated the effect and potential mechanisms of ghrelin on
Hcy-induced endothelial dysfunction. The results showed that ghrelin has a protective effect in the porcine coronary
artery and human coronary artery endothelial cells by blocking Hcy-induced endothelial dysfunction, improving
endothelial nitric oxide synthase expression, and reducing oxidative stress. Ghrelin administration may have beneficial
effects in the treatment of vascular disease in patients with hyperhomocysteinemia.Ghrelin is a 28-amino acid peptide that was first iden-
tified in the rat stomach and reported as an endogenous
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(GHS-R).1 It primarily functions to stimulate food intake
and induce adiposity through growth hormone–independent
mechanisms within the hypothalamus and stomach fundus
lining.2 Ghrelin and its receptors have been isolated from
various tissues, including the stomach, hypothalamus, pitu-
itary gland, blood vessels, and myocardium.
Recent studies focused on the cardiovascular system
have demonstrated that ghrelin is able to cause vasodila-
tion and increase cardiac index, stroke volume, left ven-
tricular contractility, and left ventricular fractional short-
ening.3,4 More notably, ghrelin has been implicated in
improving endothelial dysfunction, increasing endothe-
lial nitric oxide synthase (eNOS) expression,5 and reduc-
ing proinflammatory reactions in human endothelial
cells.6
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of ghrelin.6,7 Previous studies have demonstrated that
deacylated ghrelin (D-ghrelin), unlike the standard form of
ghrelin, does not inhibit tumor necrosis factor- (TNF-)–
induced interleukin 8 release.6,7
Cardiovascular diseases, including hypertension, coro-
nary artery disease, stroke, and congestive heart failure
affect70 million Americans and result in nearly 1 million
deaths annually.8 The major pathologic factor of these
diseases is atherosclerotic plaque formation in small and
large arteries. It is hypothesized that the pathogenesis of
atherosclerosis commences with an inflammatory process
resulting in endothelial injury and dysfunction.9
Endothelial injury causes compensatory responses that
lead to a procoagulant state as well as release of vasoactive
molecules and cytokines. The etiology of endothelial injury
relates to many factors, including hyperlipidemia, hyper-
tension, diabetes mellitus, cigarette smoking, and various
infectious agents. Elevated homocysteine (Hcy) levels have
also proven to be an under-diagnosed cause of endothelial
dysfunction. Previous studies by our laboratory have dem-
onstrated that Hcy decreases endothelium-dependent va-
sorelaxation and eNOS reactivity, causing endothelial dys-
function in porcine carotid and coronary arteries.10,11 As a
result, individuals with elevated Hcy levels are at an in-
creased risk for atherosclerosis and cardiovascular dis-
ease.12,13
This study evaluated the protective role of ghrelin on
Hcy-induced endothelial dysfunction and tested the hy-
pothesis that ghrelin may block the endothelial injury and
reduction of eNOS expression caused by Hcy. Ghrelin may
also have the capacity to reduce Hcy-induced reactive oxy-
gen species (ROS) production. These findings may have
important implications concerning ghrelin as a potential
therapy for atherosclerosis and cardiovascular disease.
MATERIALS AND METHODS
Chemicals and reagents. Human ghrelin and D-
ghrelin were obtained from Phoenix Pharmaceuticals Inc
(Belmont, Calif). Other reagents, including thromboxane A2
analog (9,11-Dideoxy-11a, 9 a-epoxymethanoprostaglandin
F2a; U46619), bradykinin, Tris-buffered saline (TBS) solu-
tion, phosphate-buffered saline (PBS) solution, and all
others, unless stated, were obtained from Sigma Chemicals
Co (St. Louis, Mo). Dulbecco modified Eagle medium
(DMEM) was obtained from Life Technologies Inc (Grand
Island, NY), and the antibiotic-antimycotic solution was
obtained from Mediatech Inc (Herndon, Va). The protein
assay kit, polyacrylamide gels, iScript cDNA Synthesis Kit,
and iQ SYBR Green SuperMix Kit were obtained from
BioRad Laboratories (Hercules, Calif). Antighrelin recep-
tor (GHS-R1a) antibody was obtained from Phoenix Phar-
maceuticals Inc. This antibody has a neutralizing activity
for ghrelin.14
Isometric tension model. The myograph tension
model using porcine coronary arteries has been previously
described by our laboratory.15 Briefly, the myograph device
(Danish Myo Technology Organ Bath 700 MO, Aarhus,Denmark) records the tension on two wires caused by
contraction of the blood vessel in response to various
reagents.
Fresh porcine hearts were harvested and stored in cold
PBS, and the right coronary artery was isolated. The artery
was then divided into 5-mm rings and incubated in DMEM
solution for 24 hours at 37° C. The rings were cultured in
the following groups: control, ghrelin (100 ng/mL), Hcy
(50 M), and ghrelin (100 ng/mL) plus Hcy (50 M).
After 24 hours of incubation, the rings were mounted
on the myograph wires in an organ bath of Krebs Henseleit
solution. The chambers were oxygenated with 100% oxy-
gen and maintained at 37° C. The rings were allowed to
equilibrate for 15 minutes after being subjected in a step-
wise fashion to a predetermined optimal tension of 30 mN.
After equilibration, vasoconstriction was induced with
the thromboxane A2 analog U46619 (3 108 M). Once
maximal contraction had reached a plateau, a concentra-
tion response curve of vasorelaxation was obtained using
endothelium-dependant vasodilator bradykinin (109 M,
108 M, 107 M, 106 M, and 105 M) at 3-minute
intervals.
Finally, to measure the full relaxation of the ring,
endothelium-independent vasodilator sodium nitroprus-
side (SNP, 105 M) was added to the organ bath. The
volume of reagents added were no more than 1% of the
total chamber volume to reach the final concentration
required. The percent relaxation was calculated based on
changes in the tension with vasodilators in relation to the
maximal contraction value.
Real-time reverse transcription-polymerase chain
reaction. After treatment with ghrelin, Hcy, or ghrelin
plus Hcy, the porcine coronary artery endothelial cells were
scraped from the rings, and their total RNA was isolated
using the Tri-Reagent kit. The iScript cDNA Synthesis Kit
was used to generate complementary DNA from isolated
messenger RNA (mRNA). The iQ SYBR Green SuperMix
Kit was then used for the real-time polymerase chain reac-
tion (PCR). The housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was applied as an
internal control for eNOS expression. A total of 1 g of
RNA was loaded for all samples.
The GAPDH (GenBank no. AF017079) primer se-
quences are 5=-TGTACCACCAACTGCTTGGC-3= forward
primer and 5=-GGCATGGACTGTGGTCATGAG-3= re-
verse primer. The eNOS (GenBank no. AY266137) primers
are 5=-CCTACCAACGGCTCCCCTC-3= forward primer
and 5=-GCTGTCTGTGTTACTGGATTC-3= reverse primer.
Real-time PCR was completed using the iCycler iQ
real-time PCR detection system. The thermal cycles for
reverse transcription included 5 minutes at 25° C, 30 minutes
at 42° C, and 5 minutes at 85° C. Real-time PCR was set for
3 minutes at 95° C, 40 repeated cycles of 20 seconds at
95° C, and 1 minute at 60° C. The sample cycle threshold
(Ct) values were assessed from plots of relative fluorescence
units (RFU) vs PCR cycle numbers during exponential
amplification so that sample measurement comparisons
were possible. The eNOS gene expression level for each
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Lucigenin-enhanced chemiluminescence with Sirius Lumi-
nometer and FB12 software (Berthold Detection
Systems GmbH, Pforzheim, Germany) was used to de-
tect superoxide anion production by endothelial cells.
Treated porcine coronary artery rings were incubated for
24 hours and then rinsed in a modified Krebs HEPES
(N-2-hydroxyethylpiperazine-N=-2-ethanesulfonic acid) buffer
solution. Each ring was cut longitudinally into an approx-
imate 5 5 mm segment. Assay tubes were filled with 500
L of Krebs HEPES buffer solution and 25-L lucigenin
(5 M). After the reagents were mixed in the tube, the
arterial segment was placed with the endothelial surface
facing the bottom of the tube. During a 12-minute period,
measurements of relative light units per second (RLU/s)
were obtained every 15 seconds, and the measurements
between 5 and 10 minutes were averaged. The area of each
arterial segment was measured with a caliper to normalize
the data for each sample with the final unit of RLU/s/
mm2.
Immunohistochemistry. Treated porcine coronary
rings were fixed overnight in 10% neutral buffered forma-
lin, embedded in paraffin, and cut into 5-m-thick cross-
sections. The sections were incubated with monoclonal
antibody against human eNOS (1:1000, BD Biosciences,
San Jose, Calif) diluted in PBS (with 5% normal horse
serum, 0.1% Triton-X 100) overnight at 4° C. After rinsing,
the sections were incubated with biotinylated antimouse
immunoglobulin G (IgG; 1:250) at room temperature for
40 minutes. For diaminobenzidine visualization, the sec-
tions were incubated in avidin-biotin-peroxidase solution
at room temperature for 1 hour, followed by 0.1% diami-
nobenzidine and 0.003% hydrogen peroxide in TBS for 10
minutes.
Next, the sections were counterstained with hematoxylin-
eosin, cover slipped, and visualized under an Olympus
BX41 microscope (Olympus USA Inc, Melville, NY). A
SPOT-RT digital camera (Diagnostic Instruments Inc,
Sterling Heights, Mich) was used to capture the images.
Cell culture. Human coronary artery endothelial cells
(HCAECs) and endothelial growth medium-2 (EGM-2)
were purchased from Cambrex BioWhittaker Inc (Walkers-
ville, Md). When the HCAECs grew to 80% to 90% con-
fluence with EGM-2 plus 10% fetal bovine serum, they
underwent serum starvation for 6 hours. The cells were
then treated with different reagents, including Hcy or
ghrelin in EGM-2 plus 2% fetal bovine serum, or both, for
24 hours. For the antighrelin receptor antibody–blocking
experiment, antibody (1:500) was preincubated with cells
for 1 hour before Hcy or ghrelin, or both, were added into
the cells.
Western blot. Total proteins were isolated from
HCAECs using cell lysis buffer (Cell Signaling Technol-
ogy, Danvers, Mass). The same amount of endothelial
proteins (6 g) was resolved electrophoretically by sodiumdodecyl sulfate polyacrylamide gel electrophoresis (10%
polyacrylamide) and transferred to the nitrocellulose filter.
The eNOS protein was detected using a mouse antihuman
eNOS monoclonal antibody diluted 1:1000 (BD Bio-
sciences), and -actin protein was detected using a mouse
antihuman -actin monoclonal antibody diluted 1:10000
(Chemicon/Millipore, Billerica, Mass). The eNOS and
-actin primary antibodies were detected with a horserad-
ish peroxidase–conjugated goat antimouse IgG secondary
antibody diluted 1:2000. Blots were developed using an
ECL Plus kit and analyzed with a gel documentation sys-
tem and analysis software (Alpha Innotech Co, San Lean-
dro, Calif).
Statistical analysis. Statistical analysis was completed
by comparing the data between treatment and control
groups using the t test (two-tail) with Minitab software
(Sigma Breakthrough Technologies Inc, San Marcos, Tex).
The bradykinin-induced vasorelaxation, eNOS mRNA,
and superoxide anion data generated from multiple groups
were analyzed by analysis of variance (ANOVA). A value of
P  .05 was considered statistically significant. Statistical
values are reported as mean  standard error of the mean.
RESULTS
Ghrelin specifically blocks Hcy-induced endothelial
dysfunction in porcine coronary arteries. Porcine coro-
nary artery rings were divided into four treatment groups:
control, ghrelin (100 ng/mL), Hcy (50 M), and ghrelin
plus Hcy. In response to the vasoconstrictor, thromboxane
A2 analog U46619 (107 M), the vessels contracted with
no significant difference among all groups (Fig 1, A). The
endothelium-dependent vasorelaxation in response to
each cumulative concentration of bradykinin was mea-
sured (Fig 1, B).
When the vasodilator bradykinin (105 M) was added
to the rings, ghrelin-treated rings responded with 66.64% 
4.23% relaxation, which was not statistically different from
the control group. Relaxation of the Hcy-treated group
(51.95% 5.27%) was reduced compared with the control
group (71.63%  2.22%, n  8; P  .05, t test and
ANOVA). However, cotreatment with ghrelin plus Hcy
resulted in relaxation of 66.4%  3.62%, similar to the
control rings. Ghrelin did not affect endothelium-independent
vasorelaxation in response to SNP in porcine coronary
artery rings (Fig 1, C).
To confirm the specificity of the action of ghrelin on
endothelial cells, nonfunctional D-ghrelin was used in the
myograph system. As expected, D-ghrelin was not able
to block the Hcy-induced inhibition of endothelium-
dependent vasorelaxation in response to bradykinin (Fig 1,
D). D-ghrelin also had no effects on vasomotor reactivities
in response to U46619 and SNP. Thus, ghrelin specifically
blocks Hcy-induced endothelial dysfunction in porcine
coronary arteries.
Ghrelin, not D-ghrelin, blocks the Hcy-induced
decrease in eNOS mRNA levels in porcine coronary
arteries. The level of eNOS mRNA in treated porcine
coronary endothelial cells was measured using real-time
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control. Treatment with ghrelin resulted in an eNOS
mRNA level of 0.014  0.002 relative unit to GAPDH,
not statistically different from 0.014  0.0003 in the
control group. A 47% reduction occurred in the eNOS
mRNA level in Hcy-treated rings (0.0095 0.0006) com-
pared with the control untreated rings (n  3, P  0.05;
Fig 2,A). However, cotreatment of ghrelin with Hcy led to
an eNOS mRNA level of 0.013  0.0018, which was
similar to the control group but significantly higher than
that in the Hcy group (n 3, P .05, t test and ANOVA;
Fig 2, A). By contrast, nonfunctional D-ghrelin was not
able to block the Hcy-induced decrease in eNOS mRNA
levels in porcine coronary arteries (Fig 2, B). Thus, ghrelin
specifically blocks Hcy-induced eNOS down-regulation in
porcine coronary artery rings.
Ghrelin blocks the Hcy-induced decrease in
eNOS immunoreactivity in porcine coronary arteries.
Immunohistochemical staining for eNOS protein was per-
formed in control, ghrelin, Hcy, and ghrelin plus Hcy
treated porcine coronary artery rings. As depicted in Fig 3,
eNOS immunoreactivity of porcine coronary artery rings
treated with ghrelin reveals the same intensity of staining as
the control rings. Treatment with Hcy resulted in a reduc-
tion of eNOS staining; however, the addition of ghrelin to
Hcy resulted in eNOS staining intensity returning to the
control level.
Ghrelin blocks the Hcy-induced increase in super-
oxide anion in porcine coronary arteries. To determine
whether ghrelin could block Hcy-induced oxidative stress,
a key molecular event of Hcy vascular pathogenesis, the
production of superoxide anion, a major type of ROS, was
analyzed with the lucigenin-enhanced chemiluminescence
method. As shown in Fig 4, an 117% increase occurred in
the amount of superoxide anion production in Hcy-treated
rings (25.2 2.7 RLU/s/mm2) vs control rings (11.58
1.1 RLU/s/mm2, n  8; P  .05, t test and ANOVA).
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Fig. 1. Effects of ghrelin and homocysteine (Hcy) on vasomotor
functions in porcine coronary arteries. The vessel rings (n  8)
were treated with or without ghrelin, Hcy, or Hcy plus ghrelin, for
24 hours. Vasomotor reactivity was determined by the myograph
system in response to vasoactive drugs. Error bars represent the
standard error of the mean. A, Vessel contraction in response to
the thromboxane A2 analog U46619 (107 M). B, Endothelium-
dependent vasorelaxation in response to accumulative concentrations
of bradykinin (109 to 105 M). C. Endothelium-independent
vasorelaxation in response to sodium nitroprusside (SNP, 105 M).
D. Effects of deacylated ghrelin (D-ghrelin) and Hcy on vasomo-
tor functions in porcine coronary arteries. The vessel rings were
treated with or without D-ghrelin, Hcy or Hcy plus D-ghrelin for
24 hours. The vessel rings were precontracted with the thrombox-
ane A2 analog U46619 (107 M), and endothelium-dependent
vasorelaxation was recorded in response to accumulative concen-
trations of bradykinin (109 to 105 M). B and D, *P  .05 by t
test and analysis of variance. B, C, and D, EC, Endothelial cell.
Relative unit to GAPDH.
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of 13.26  0.8 RLU/s/mm2, which was not statistically
different from the control. The addition of ghrelin to
Hcy-treated rings led to a superoxide anion production of
15.57  1.4 RLU/s/mm2, which was similar to the con-
trol group. Thus, ghrelin was able to significantly reduce
superoxide anion production by 61% vs that in Hcy-treated
vessels (n  8, P  .05; Fig 4).
Ghrelin, not D-ghrelin, blocks the Hcy-induced
decrease in eNOS protein levels in HCAECs. HCAECs
were treated with Hcy (50 M) for 24 hours, and eNOS
protein levels were determined by Western blot analysis and
band intensity quantitation. Homocysteine substantially
decreased eNOS protein levels, whereas ghrelin effectively
Fig 2. Effects of ghrelin, deacylated ghrelin (D-ghrelin), and homo-
cysteine (Hcy) on endothelial nitric oxide synthase (eNOS)messenger
RNA (mRNA) levels in porcine coronary arteries. The vessel rings
(n 3) were treated with or without ghrelin, D-ghrelin, Hcy, or Hcy
plus ghrelin or D-ghrelin for 24 hours. The mRNA levels of porcine
eNOS and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were determined by real time polymerase chain reaction. A. Effects of
ghrelin and Hcy. B. Effects of D-ghrelin and Hcy. Relative eNOS
mRNA levels were calculated as 2 [Ct(GAPDH)-Ct(eNOS)]; *P  .05.
Both t test and analysis of variance were performed. Error bars show
the standard error of the mean.blocked the Hcy-induced decrease in eNOS protein levelsin a concentration-dependent manner (Fig 5, A). How-
ever, D-ghrelin (100 ng/mL) did not have the blocking
effects of ghrelin (Fig 5, B). Furthermore, neutralizing
antibody against the ghrelin receptor (GHS-R1a, 1:500
dilution) effectively inhibited the blocking effect of ghrelin
on the Hcy-induced decrease in eNOS protein levels in
HCAECs (Fig 5, C). Thus, ghrelin has a receptor-dependent
effect.
DISCUSSION
Ghrelin, a ligand for the growth hormone secretagogue
receptor (GHS-R), has been extensively studied in relation
to obesity and appetite suppression. A recent cohort study
of obesity related to atherosclerosis found a direct link
between the two factors. The authors noted a greater risk of
coronary artery calcium (17%), internal carotid artery intima-
media thickness (32%), common carotid artery intima-
media thickness (45%), and increased left ventricular
mass.16 Basal plasma ghrelin was significantly lower in the
patients with obesity-associated metabolic syndrome than
in healthy controls.17
The metabolic and cardiovascular effects of ghrelin
are believed to be mediated by both growth hormone-
dependent and independent mechanisms.18 Nagaya et al3
showed that the administration of ghrelin to healthy adults
leads to an increase in cardiac index and stroke volume
without an increase in the heart rate and plasma norepi-
nephrine levels. The administration of intravenous ghrelin
has also been beneficial in myocardial reperfusion injury
and cardiac cachexia due to probable inhibition of cytokine
release. Specifically, ghrelin may inhibit basal and TNF-–
induced chemotactic cytokine production and mononu-
clear cell adhesion, promoting improved cardiovascular
health and function.6
In the current study, ghrelin was used as a protective
agent to effectively block Hcy-induced endothelial dys-
function, eNOS down-regulation, and oxidative stress in
porcine coronary arteries. The specific concentration of
ghrelin (100 ng/mL) was selected from previous studies
and documented plasma levels.12,19-21 Human physiologic
plasma concentration of ghrelin was reported at about 0.75
ng/mL; however, one study noted that physiologic plasma
ghrelin levels in healthy adults were 20.35  5.10 ng/
mL.22 In many in vitro studies, much higher concentra-
tions of ghrelin are used, such as 100 ng/mL.6,23,24
Although this concentration is much higher than physio-
logic levels, it may have therapeutic values. For therapeutic
purpose, we also used this concentration (100 ng/mL) to
effectively block Hcy-induced endothelial dysfunction in por-
cine coronary arteries. Furthermore, we have performed addi-
tional experiments using HCAECs. Different concentrations
of ghrelin (0.5, 5, 50, and 100 ng/mL) were used in the
experiments. Ghrelin effectively blocked an Hcy-induced de-
crease in eNOS protein levels at 50 and 100 ng/mL.
Hyperhomocysteinemia (Hcy 100 M) is a rare in-
born error of metabolism that has been correlated with
premature vascular diseases, including thromboembolic
events and atherosclerosis. It typically presents in the third
were performed.
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of individuals experience acute thromboembolic events
with a 20% mortality rate.25 The severe form results from a
genetic error resulting in a deficiency of cystathionine
	-synthase.13 A more common and milder form of the
disorder may be induced by various nutritional deficiencies
(folate, vitamin B12, and vitamin B6), chronic diseases (eg,
renal failure, pernicious anemia, and hypothyroidism), and
various medications and toxins.13
Hcy is believed to affect the coagulation system as well
as the resistance of endothelial cells to thrombosis and the
vasodilatory function of nitric oxide (NO).12 Nygård et al13
demonstrated a concentration-dependant relation between
total plasma Hcy levels and death from cardiovascular
causes. These studies along with our previous study were
used to select the appropriate concentration of Hcy (50
M) used in the current investigation.10,11
Through previous experiments, our laboratory has es-
tablished and characterized an in vitro culture model of
porcine coronary artery rings using myograph analy-
sis.10,11,26-28 Endothelium-dependent vasorelaxation was
analyzed based on a challenge of bradykinin, a potent
vasodilator that acts through endothelial B2 kinin receptors
to stimulate the release of NO through eNOS activation.29
Several clinical risk factors or molecules have been exam-
ined by our laboratory to find the effect on endothelial
. Homocysteine
. Hyc + Ghr
helial nitric oxide synthase (NOS) immunoreactivity in
without ghrelin, Hcy, or Hcy plus ghrelin for 24 hours.
immunohistochemical staining. A, Control. B, Homo-
elin. Original magnification 400.A. Control B
C. Ghrelin D
Fig 3. Effects of ghrelin and homocysteine (Hcy) on endot
porcine coronary arteries. The vessel rings were treated with or
Porcine eNOS protein levels (arrows) were determined with
cysteine (Hcy). C, Ghrelin (Ghr). D, Homocysteine plus ghrFig 4. Effects of ghrelin and homocysteine (Hcy) on superoxide
anion production in porcine coronary arteries. The vessel rings
(n  8) were treated with or without ghrelin, Hcy, or Hcy plus
ghrelin for 24 hours. Superoxide anion production from the
endothelial surface of porcine coronary rings was detected by
lucigenin-enhanced chemiluminescence. Relative light units per
second (RLU/s) were recorded and the measurements between 5
and 10 minutes were averaged and normalized to the area of each
arterial segment as RLU/s/mm2. Error bars show the standard
error of the mean. *P  .05; both t test and analysis of variancefunctions.10,11,26-28
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damaging effects of Hcy on the porcine coronary artery.
Myograph data showed that Hcy reduced endothelium-
Fig 5. Effects of ghrelin and homocysteine (Hcy) on endothelial
nitric oxide synthase (eNOS) protein levels in human coronary
artery endothelial cells (HCAECs). The cells were treated with or
without ghrelin, Hcy (50 M), or Hcy plus ghrelin (100 ng/mL)
for 24 hours. Human eNOS protein levels were determined with
Western blot and band intensity quantitation. Error bars show the
standard error of the mean. A, Ghrelin concentration-dependent
study (0, 0.5, 5, 50, and 100 ng/mL). B, Effect of D-ghrelin (100
ng/mL). C, Blocking effect of antighrelin receptor antibody (anti-
GHS-R1a Ab, 1:500).dependent vasorelaxation in coronary vessels by 31% com-pared with untreated controls. Cotreatment with ghrelin,
however, effectively blocked the Hcy-induced decrease in
endothelium-dependent vasorelaxation. Importantly, D-
ghrelin did not change the Hcy-induced reduction in va-
sorelaxation. This suggests that the functionality and mech-
anism of ghrelin on the endothelium depends on the
acylated portion of the molecule.
A limitation in the current report could be that the
time-course study was not performed in the porcine coro-
nary artery model because the 24-hour time point is the
optimal time for this model system. Because the porcine
coronary preconditioning in the culture system requires
certain hours, the vascular response of these vessel rings is
not sensitive or consistent to certain reagents, including
Hcy and ghrelin, at earlier time points.
Central to vascular biology and endothelial cell homeosta-
sis is the regulation of NO bioavailability. NO is generated by
eNOS and is a potent vasodilator with multiple cardiovascular
functions. Patients with eNOS polymorphism and a reduction
in eNOS reactivity exhibit higher rates of myocardial events.30
The observed changes in the current study within endotheli-
um-dependent relaxation are primarily due to a decrease in
eNOS expression. This theory was confirmed by real-time
PCR data showing a significant decrease in eNOS mRNA
levels of Hcy-treated porcine coronary artery rings and then an
increase to control levels when treated with ghrelin. A 31%
reduction of eNOS mRNA levels in Hcy-treated porcine
coronary artery rings compared with control rings may ac-
count for the Hcy-induced inhibition of endothelium-depen-
dent vasorelaxation. When Hcy-treated artery rings were then
combined with ghrelin and incubated for 24 hours, only a 7%
reduction from control eNOS mRNA levels was observed.
Immunoreactivity of eNOS was reduced in Hcy-treated ves-
sels; however, the ability to block Hcy with cotreatment of
ghrelin was confirmed as eNOS staining returned to near
control levels.
These findings, together with the functional data ob-
tained from myograph analysis, suggest a potential mecha-
nism of improved function and reversal of Hcy-induced
damage to endothelial cells by increased eNOS expression
and NO bioavailability by treatment with ghrelin. Further-
more, we have performed several new experiments using
HCAECs. Specifically, we treated HCAECs with Hcy (50
M) for 24 hours and determined eNOS protein levels by
Western blot analysis and band intensity quantitation. We
showed that Hcy substantially decreased eNOS protein
levels. Different concentrations of ghrelin (0.5, 5, 50, and
100 ng/mL) were used in the experiments. Ghrelin did
indeed effectively block the Hcy-induced decrease in eNOS
protein levels in a concentration-dependent manner; how-
ever, D-ghrelin did not have such blocking effects. A neu-
tralizing antibody against ghrelin receptor (GHS-R1a) ef-
fectively inhibited the blocking effect of ghrelin on the
Hcy-induced decrease in eNOS protein levels in HCAECs.
Thus, the effect of ghrelin is a receptor-dependent.
Disproportion in the quantity of ROS generated dur-
ing aerobic metabolism is known to lead to oxidative stress
and contributes to vascular disease. This process occurs
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tion and depletion,31 intracellular alkalinization,32 and reg-
ulation of gene transcription.33 The chemiluminescence
method is a reliable and reproducible method for measur-
ing ROS production.34 In the present analysis, ghrelin
reduced the production of superoxide anion, a major type
of ROS, in Hcy-treated rings. These outcomes are compa-
rable to work done in other laboratories. Iantorno et al5
demonstrated that ghrelin stimulates endothelial cell NO
production through GHS-R1a, phosphoinositide 3-kinases,
and Akt pathways, thereby improving endothelial function.
Shimizu et al1 showed that administration of ghrelin to rats
deficient in growth hormone led to improved vasorelax-
ation and increased eNOS expression of the thoracic aorta.
The major enzymatic activity of eNOS is to convert
L-arginine to L-citrulline and NO. This enzyme activity is
maintained by the coenzyme component tetrahydrobiopterin
(BH4) and a sufficient level of L-arginine. However, if BH4 or
L-arginine, or both, are low or not available to eNOS, eNOS
can activate oxygen and generate superoxide free radicals, but
not NO. This process is termed “eNOS uncoupling,” and it
has a negative effect on endothelial functions.
Several compounds, including lucigenin, nitroblue tet-
razolium, 2,6-dichlorophenolindophenol, and quinones
can cause eNOS uncoupling.35,36 A previous study dem-
onstrated that Hcy could cause eNOS uncoupling and
increased superoxide anion production though alteration
of intracellular BH4 availability.37 Thus, it is possible that
increased superoxide anion could be generated from eNOS
uncoupling in the current study.
In addition, we did not confirm whether reduced NO
availability is solely responsible for the Hcy-induced de-
crease in endothelium-dependent relaxation and the in-
crease in superoxide production. The application of an
eNOS inhibitor such as NG-nitro-L-arginine methyl ester
(L-NAME) in combination with Hcy in the experimental
models could address this important issue. Thus, further
investigations are warranted.
Mechanistic aspects of superoxide production related
to ghrelin have been reported.34 Li et al6 examined the role
of proinflammatory cytokines, reporting that ghrelin inhibits
the TNF-–induced interleukin 8 release in a concentration-
dependent manner. Mononuclear cell adhesion molecules
have been an integral part of vascular inflammation and
atherosclerosis, induced by chemotactic cytokines. Ghrelin
inhibits the activity of nuclear factor-
B, crucial in the
production of chemotactic cytokines and adhesion mole-
cule expression that adversely affects endothelial cell re-
sponse.6 Ghrelin has also been shown to improve left
ventricular function in heart failure.15,38
In our previous studies of NADPH oxidase subunits,
we noted an increase in the protein expression of these
subunits. Also, dihydroethidium staining and flow cytom-
etry analysis showed a decrease in mitochondrial membrane
potential indicating an increase in free oxygen radical spe-
cies from mitochondrial dysfunction.39,40 Xu et al41
showed that ghrelin time-dependently stimulated Akt and
adenosine 5=-monophosphate-activated protein kinase(AMPK) phosphorylation in both cultured endothelial cells
and intact vessels. Also, the mechanism of action of ghrelin
on endothelial cells may be linked to the GHS-R, a seven-
transmembrane G protein-coupled ghrelin receptor. Stimula-
tion of GHS-R with ghrelin leads to activation of G protein,
calcium mobilization, and multiple downstream signaling.41
Besides the detrimental effects of Hcy on cardiovascu-
lar system,10,13 the elevation of Hcy levels is also associated
with peripheral arterial disease as well as venous disease
such as deep venous thrombosis.42 Thus, the effects of Hcy
are present in other peripheral vascular beds besides coronary
arteries. However, few published reports refer to the effect of
ghrelin on peripheral vascular disease. On the basis of the
blocking effect of ghrelin on Hcy-induced vascular damage,
our data may be extrapolated to other areas of the vasculature.
Although strong evidence suggests that ghrelin leads to
increased food intake and increased lipid deposition, its
cardiovascular benefits, such as inhibition of cytokine pro-
duction and improved left ventricular function, have also
been well documented. Ghrelin receptors have been iso-
lated in various tissues such as endocrine glands and cardio-
vascular tissues. In addition, receptor density changes have
been demonstrated as an important part of the cardiovas-
cular effects of ghrelin.43 Targeting the specific tissue re-
ceptors with modification of the ghrelin molecule may
achieve the desired cardiovascular effects without activating
the unwanted effects of ghrelin.
CONCLUSION
Ghrelin is a potent and effective protein that inhibits
the effects of Hcy and other potentially damaging mecha-
nisms on endothelium-dependent vasorelaxation in por-
cine coronary arteries. The mechanism of improvement in
endothelial function relates to improved eNOS expression
and a reduction in oxidative stress. Ghrelin also has a potent
effect on blocking the Hcy-induced decrease in eNOS
protein levels in HCACEs in a concentration-dependent
manner, and its effect is GHS-R1a specific. Enhanced eNOS
expression leading to an increase in NO release is an important
factor in the treatment of atherosclerosis. As an increasing
number of patients with premature vascular disease are being
diagnosed with hyperhomocysteinemia, the potential for the
treatment of these individuals with ghrelin warrants further
investigation and may lead to exciting new therapies.
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